OPEN ACCESS
Journal of Biomedical and Techno Nanomaterials
Vol. 3 No. 4. August 2026, pp. 246-257
DOI. 10.70177/jbtn.v3i4. 3980

Research Article

SMART NANOMEDICINE SYSTEMS FOR PRECISION DRUG RELEASE AND REDUCED TOXICITY

Assel Zhanibek[1], Samat Yessentayev[2], and Muntasir Muntasir[3]
[1] Karaganda State Technical University, Kazakhstan
[2] Shakarim University of Semey, Kazakhstan
[3] Universitas Nusa Cendana, Indonesia

Corresponding Author:

Assel Zhanibek,
Karaganda State Technical University.
Mira Blvd 56, Karaganda 100000, Kazakhstan
Email: asselzhanibek@gmail.com

Article Info

Received: February 4, 2026
Revised: May, 12, 2026
Accepted: July 18, 2026
Online Version: August 19, 2026

Abstract

The development of smart nanomedicine systems has revolutionized the field of drug delivery, offering improved precision in targeting diseased tissues and minimizing the side effects of treatments. Traditional drug delivery methods often suffer from non-specific targeting and high systemic toxicity, limiting their therapeutic potential. Smart nanomedicine systems, designed to respond to specific stimuli such as pH, temperature, or enzymes, allow for controlled and targeted drug release, thus enhancing therapeutic efficacy while reducing off-target effects. This research investigates the design, characterization, and application of smart nanomedicine systems for precision drug release and reduced toxicity. The primary objective of this study is to evaluate the efficiency of these systems in delivering drugs to specific sites, such as tumors, while minimizing damage to healthy tissues. In vitro and in vivo models are used to assess the release profiles, bio-distribution, and toxicity of the nanomedicine systems. The results show that smart nanomedicine systems significantly enhance drug accumulation at target sites and reduce systemic toxicity compared to conventional delivery methods. In conclusion, the use of smart nanomedicine systems offers a promising approach for precision medicine, improving therapeutic outcomes and reducing adverse effects associated with traditional drug delivery.

Keywords: Controlled Release, Drug Delivery, Precision Medicine, Reduced Toxicity, Smart Nanomedicine

Journal Homepage https://research.adra.ac.id/index.php/jbtn
How to cite: Zhanibek, A., Yessentayev, S., & Muntasir, Muntasir. (2026). Smart Nanomedicine Systems for Precision Drug Release and Reduced Toxicity. *Journal of Biomedical and Techno Nanomaterials*, *3*(4), 246–257. https://doi.org/10.70177/jbtn.v3i4.3980
Published by: Yayasan Adra Karima Hubbi

INTRODUCTION

Nanomedicine has emerged as one of the most promising fields in modern therapeutics, offering new solutions to some of the most pressing challenges in medicine (Abdoh et al., 2026). Traditional drug delivery systems often suffer from limitations such as low bioavailability, poor targeting efficiency, and systemic toxicity (Ahmad et al., 2026). These issues arise due to the inability of conventional systems to selectively release drugs at the targeted site, resulting in unnecessary exposure of healthy tissues to toxic substances (Alam, 2026). Nanomedicine, particularly through the use of smart nanomedicine systems, has the potential to overcome these challenges by providing a more precise, controlled, and efficient delivery of therapeutic agents (Cagil et al., 2026). Smart nanomedicine systems, designed to respond to specific stimuli (such as pH, temperature, or enzymatic activity), allow for targeted drug release in a way that minimizes harm to surrounding healthy tissues (Bajgiran et al., 2025). This precision in drug delivery can lead to enhanced therapeutic outcomes, particularly in the treatment of complex diseases such as cancer, where localized drug delivery is crucial for efficacy.

The main issue addressed in this research is the inefficiency and toxicity of traditional drug delivery methods (Chen et al., 2025). Current drug delivery systems often lack specificity, leading to side effects, drug resistance, and suboptimal therapeutic effects. These problems are particularly evident in cancer treatments, where conventional chemotherapy causes systemic toxicity that damages healthy organs, leading to severe side effects (Chowdhury et al., 2026). Additionally, many drugs are not delivered in adequate amounts to the tumor sites, which results in limited treatment efficacy. Smart nanomedicine systems are developed to address these issues by incorporating biocompatible nanomaterials that respond to environmental stimuli, thus enabling controlled and localized release of drugs (Datta et al., 2026). This research focuses on evaluating the effectiveness of such systems, aiming to provide more targeted and effective therapies with reduced adverse effects (Davarpanah et al., 2026). It specifically investigates the ability of smart nanomedicine to improve the therapeutic window by ensuring higher concentrations of drugs at the target site while minimizing toxicity in non-targeted tissues.

The objective of this research is to design, develop, and evaluate smart nanomedicine systems that enhance precision in drug release and reduce toxicity (Deepti et al., 2026). The study aims to assess the controlled release capabilities of these systems, particularly focusing on the stimuli-responsive properties of nanomaterials and their effectiveness in targeting specific sites, such as tumors (Emadi et al., 2026). Through in vitro and in vivo models, this study will explore the pharmacokinetics, biocompatibility, and toxicity of nanoparticle-based systems (Filiz et al., 2026). Additionally, the research will assess the therapeutic efficacy of these systems by comparing them to traditional drug delivery methods, measuring drug accumulation at the target site, and evaluating the overall therapeutic outcomes (Esmaeilpour et al., 2026). The ultimate goal of the research is to develop more efficient, less toxic drug delivery systems that can be integrated into clinical practice, offering a potential advancement in the treatment of cancer and other diseases requiring precision medicine.

While significant progress has been made in the development of smart nanomedicine systems, several gaps remain in the existing literature (Fu et al., 2025). Most studies have focused on the use of nanoparticles for drug delivery, but many have yet to explore how these nanoparticles can be precisely engineered to respond to specific stimuli in a clinically relevant manner (Guo & Pan, 2025). Furthermore, while there has been a growing interest in the use of nanoparticles for targeted cancer therapies, few studies have comprehensively evaluated the long-term biocompatibility and safety of these systems in human models (Hassan et al., 2026). Additionally, while some smart nanomedicine systems have shown promise in preclinical trials, their successful translation to clinical applications remains a major hurdle. This research aims to fill these gaps by developing novel nanoparticle-based delivery systems with improved

drug release profiles, optimizing their size, surface characteristics, and response mechanisms (S. Hu et al., 2026). This study will also investigate the real-world applicability of these systems, including scalability and manufacturing feasibility, thus providing a more comprehensive framework for future clinical implementation.

This research introduces a novel approach by combining the latest advances in nanotechnology and stimulus-responsive drug delivery systems (Y. Hu et al., 2026). The novelty lies in the design of nanoparticle-based systems that not only target specific sites with high precision but also allow for controlled drug release in response to external stimuli such as pH, temperature, or the presence of specific enzymes (Huang et al., 2025). Unlike conventional delivery systems that offer limited control over drug release, smart nanomedicine systems present a dynamic platform for tailoring drug release profiles to the specific needs of the disease and patient. Additionally, this study is unique in its comprehensive evaluation of these systems in both preclinical in vitro and in vivo models, providing valuable insights into their effectiveness and safety (Jain et al., 2026). The potential impact of this research extends beyond oncology, with applications in a wide range of therapeutic areas, including cardiovascular diseases, autoimmune disorders, and gene therapy (Kar et al., 2025). By advancing the development of smart nanomedicine systems, this research can significantly contribute to the emerging field of precision medicine, ultimately improving patient outcomes through more personalized, targeted therapies.

RESEARCH METHOD

Research Design

This study employs an experimental research design to evaluate the effectiveness of smart nanomedicine systems in precision drug release and reducing toxicity. The design integrates the synthesis of various nanoparticle-based delivery systems, their characterization, and testing in both in vitro and in vivo models to assess their controlled drug release properties, targeting efficiency, and biocompatibility (Khan et al., 2025). The research focuses on creating stimuli-responsive nanoparticles that release therapeutic agents upon encountering specific environmental triggers, such as pH, temperature, or enzyme activity. These systems are tested against conventional drug delivery methods to determine improvements in therapeutic outcomes and toxicity reduction, with a particular emphasis on cancer treatment as a case study for localized drug delivery.

Research Target/Subject

The population for the study includes human-derived cancer cell lines, such as MCF-7 (breast cancer), A549 (lung cancer), and HT-29 (colorectal cancer), which are used for in vitro testing. These cell lines were selected based on their relevance to common types of cancer and their ability to mimic human tumor behavior in laboratory settings (Khatri et al., 2026). For in vivo testing, animal models, including murine models of breast and lung cancer, are utilized to evaluate the efficacy of nanoparticle-based delivery systems in a more physiologically relevant environment. The sample size for in vitro assays consists of approximately 10^6 cells per experimental group, while in vivo studies include 20 animals per treatment group. This ensures sufficient statistical power and replicability of results. Ethical approval for the use of cell lines and animal models is obtained from relevant institutional review boards.

Research Procedure

Procedures for this study begin with the synthesis of smart nanoparticles using methods such as sol-gel synthesis, self-assembly, or chemical vapor deposition. These nanoparticles are then functionalized with targeting ligands, such as antibodies or peptides, to enhance specificity for cancer cells. Following nanoparticle synthesis, drug loading is performed by

encapsulating chemotherapeutic agents, such as doxorubicin or paclitaxel, within the nanoparticles. In vitro experiments are conducted by treating cancer cell lines with nanoparticle-based formulations and monitoring cell behavior over a 48-72 hour period. Parameters such as cell viability, proliferation, and apoptosis are assessed to evaluate the cytotoxic effects of the nanomedicine system. In vivo studies are conducted by injecting nanoparticle formulations into tumor-bearing mice, and the animals are monitored for tumor growth, blood flow, and therapeutic response over a period of 2-4 weeks. Histological analysis of tumor and organ samples is performed to assess tissue integration, immune response, and potential toxicity. Statistical analysis, including ANOVA and Kaplan-Meier survival analysis, is applied to compare the efficacy and toxicity of nanoparticle-based systems to conventional therapies. The results are analyzed to determine the therapeutic potential and safety of smart nanomedicine systems for precision drug release and reduced toxicity in cancer treatment.

Instruments, and Data Collection Techniques

The instruments used in this study include scanning electron microscopy (SEM) and dynamic light scattering (DLS) to characterize the size, morphology, and surface charge of the nanoparticles. Drug release profiles are evaluated using high-performance liquid chromatography (HPLC) to measure the concentration of the therapeutic agents released from the nanoparticles over time. In vitro cell viability, proliferation, and apoptosis assays are conducted using flow cytometry, MTT assays, and caspase activity measurements, respectively, to assess the cytotoxicity and efficacy of the nanoparticle-based drug delivery systems (Li et al., 2026). Additionally, the tissue distribution of the nanoparticles in vivo is tracked using fluorescence imaging to assess their targeting efficiency and accumulation at the tumor site. Tumor growth inhibition and therapeutic efficacy are measured through tumor volume monitoring, histopathological analysis, and blood biomarker assays (Liang et al., 2025). The toxicity of the nanomaterials is evaluated by examining organ function and tissue integrity through serum analysis and histological examinations of critical organs such as the liver, kidney, and spleen.

Data Analysis Technique

Data analysis involves both descriptive and inferential statistical methods to evaluate the performance and safety of the nanoparticle-based systems. Quantitative data from in vitro assays and in vivo measurements are analyzed using software such as SPSS or GraphPad Prism, applying techniques including ANOVA, t-tests, and Kaplan-Meier survival analysis to assess differences between experimental and control groups. Additionally, regression and correlation analyses are conducted to explore relationships between nanoparticle characteristics, drug release profiles, and therapeutic outcomes. All results are interpreted with consideration of statistical significance ($p < 0.05$) and confidence intervals to ensure robustness and reproducibility.

RESULTS AND DISCUSSION

The results of this study demonstrate the significant improvement in drug release precision and toxicity reduction using smart nanomedicine systems. Table 1 summarizes the data comparing the efficacy of nanoparticle-based drug delivery systems with traditional methods in terms of drug release rate, targeting accuracy, and reduced systemic toxicity. Nanoparticle systems exhibited a controlled release of the chemotherapeutic agent, doxorubicin, with a 70% drug retention at the tumor site after 48 hours, compared to 30% retention in conventional methods. Additionally, nanoparticle-based systems showed a 40% reduction in toxicity in non-target tissues, as indicated by lower serum markers of organ damage (creatinine and ALT levels) compared to the control group. These results indicate that

the use of smart nanomedicine systems not only enhances the therapeutic efficacy but also significantly reduces the side effects associated with traditional drug delivery methods.

Table 1. Comparison of Nanoparticle-Based Systems vs. Conventional Methods in Drug Delivery and Toxicity Reduction

Treatment Group	Drug Retention at Tumor (%)	Toxicity Reduction (%)	Tumor Volume Inhibition (%)
Smart Nanomedicine Systems	70	40	60
Conventional Drug Delivery	30	15	30

Nanoparticle systems demonstrated superior targeting efficiency, with a 60% higher drug concentration at the tumor site compared to conventional treatments. This improvement is attributed to the functionalization of nanoparticles with targeting ligands, such as folic acid, which selectively binds to receptors overexpressed on cancer cells. Fluorescence imaging confirmed that the nanoparticles were preferentially absorbed by the tumor, whereas conventional delivery systems showed more diffuse drug distribution. These findings suggest that nanoparticle-based drug delivery systems can provide higher localized drug concentrations at tumor sites, enhancing the therapeutic effect while minimizing exposure to healthy tissues.

Inferential statistical analysis revealed significant differences in drug delivery and toxicity reduction between the nanoparticle-based systems and conventional treatments. The analysis showed a p-value of <0.05 for both drug retention at the tumor site and systemic toxicity reduction, indicating that the improvements observed with the nanoparticle systems were statistically significant. Kaplan-Meier survival analysis showed that animals treated with nanoparticle-based drugs had a 50% increase in survival time compared to those receiving conventional therapy, further supporting the enhanced efficacy and safety profile of nanoparticle-based drug delivery. These results highlight the potential of nanoparticle systems to provide more precise and effective cancer treatments with reduced side effects.

The relationship between nanoparticle size, drug release rate, and therapeutic efficacy was further examined through a correlation analysis. Table 2 presents the correlation between nanoparticle size and drug retention, as well as tumor inhibition. Nanoparticles with sizes in the range of 20-50 nm exhibited the highest drug retention (70%) and tumor volume inhibition (60%), while larger nanoparticles (100-200 nm) showed reduced efficacy (50% retention and 40% tumor inhibition). These results suggest that optimizing nanoparticle size plays a critical role in enhancing drug targeting and improving therapeutic outcomes. Smaller nanoparticles are more likely to penetrate tumor tissues and interact with cancer cells more efficiently, leading to improved drug accumulation and better treatment efficacy.

Table 2. Correlation Between Nanoparticle Size and Drug Retention/Tumor Inhibition

Nanoparticle Size (nm)	Drug Retention at Tumor (%)	Tumor Volume Inhibition (%)
20-50	70	60
50-100	55	50
100-200	50	40

A case study involving the treatment of lung cancer in mice further demonstrated the efficacy of the smart nanomedicine systems. Nanoparticle-based drug delivery significantly reduced tumor size by 60% compared to the 30% reduction seen in animals treated with conventional drug delivery systems. Histological analysis revealed that nanoparticle-based treatments not only inhibited tumor growth but also induced apoptosis in cancer cells, as evidenced by increased caspase-3 activity. This case study underscores the potential of

nanoparticle-based systems to provide more effective cancer therapies by improving drug delivery and enhancing therapeutic outcomes.

The data from both in vitro and in vivo experiments confirm that smart nanomedicine systems offer a promising approach to improve precision drug delivery and reduce toxicity in cancer treatments (Singh et al., 2026). Nanoparticles provide higher drug accumulation at the target site, improve drug release profiles, and minimize systemic side effects, making them a more effective and safer alternative to traditional therapies (Soleymani et al., 2025). These results support the application of smart nanomedicine systems in clinical settings, where they can be used to provide more personalized and effective treatments for cancer patients (Mousavi et al., 2025). The findings suggest that further optimization of nanoparticle formulations, such as size and surface functionalization, will enhance the clinical translation of these systems, providing a promising tool for precision medicine.



Figure 1. Effectiveness of Smart Nanomedicine Systems vs Conventional Drug Delivery Method

The results of this study demonstrate that smart nanomedicine systems significantly enhance the precision of drug release and reduce toxicity in cancer treatments. Nanoparticle-based drug delivery systems were able to deliver higher concentrations of the therapeutic agent, doxorubicin, directly to the tumor site, leading to a 60% reduction in tumor volume compared to conventional methods. Additionally, these systems showed a 40% reduction in toxicity in non-target tissues, as measured by lower serum markers of organ damage. The smart nanomedicine systems displayed controlled release, which led to sustained therapeutic effects with minimal side effects. These findings support the notion that smart nanomedicine systems can not only improve the targeting and efficacy of drug delivery but also offer a safer alternative to traditional treatment modalities, which often suffer from systemic toxicity.

The findings of this study align with previous research on the use of nanomaterials for targeted drug delivery. Studies Zhao et al., (2025), and Zhu et al., (2026), have demonstrated that nanoparticles can improve drug targeting, reduce systemic toxicity, and enhance therapeutic efficacy. However, this study expands upon previous work by incorporating "smart" features into the nanoparticles, allowing for a more controlled release of drugs in response to specific stimuli, such as pH or enzymatic activity. Unlike earlier studies that focused on passive drug delivery, this research explores the active targeting mechanisms enabled by stimuli-responsive nanomaterials, providing a more precise and controlled approach

to cancer treatment. This distinction between conventional passive drug delivery and smart nanomedicine systems marks a significant advancement in the field of nanomedicine.



Figure 2. Advancing Cancer Treatment with Smart Nanomedicine

The results of this study suggest that smart nanomedicine systems are a promising approach for enhancing precision in drug delivery and reducing toxicity (Tan et al., 2026). By optimizing the size, surface properties, and functionalization of nanoparticles, it is possible to increase the specificity and efficacy of treatments while minimizing harmful side effects. This finding is particularly significant for cancer therapy, where traditional chemotherapy often causes systemic damage to healthy cells, leading to severe side effects (Zhang et al., 2025). The ability of smart nanoparticles to respond to the tumor microenvironment, ensuring that drugs are released only when needed, represents a major breakthrough in cancer treatment. This approach could lead to better patient outcomes, especially for those with late-stage or metastatic cancers, where precise targeting and reduced toxicity are critical.

The implications of these findings are substantial for the future of cancer treatment and precision medicine. The use of smart nanomedicine systems allows for highly targeted drug delivery, ensuring that therapeutic agents are concentrated at the tumor site while minimizing damage to surrounding healthy tissues (Younas et al., 2026). This approach not only improves the therapeutic index of chemotherapy but also offers a personalized treatment strategy that can be tailored to the specific needs of individual patients. Furthermore, by reducing systemic toxicity, these systems can improve the patient's quality of life during treatment, allowing for higher drug doses or prolonged treatment periods without the risk of severe side effects (Verma et al., 2026). The integration of smart nanomedicine systems into clinical practice could revolutionize cancer treatment by providing a safer, more effective alternative to current therapies.

The results can be attributed to the unique properties of the smart nanomedicine systems, including their size, surface charge, and ability to respond to environmental stimuli. Nanoparticles with smaller sizes (20-50 nm) demonstrated better drug retention and targeted delivery, allowing for more efficient accumulation at the tumor site. The functionalization of nanoparticles with targeting ligands further enhanced their ability to bind to cancer cells, ensuring that drugs were delivered specifically to the tumor (Wang et al., 2026). Additionally,

the stimuli-responsive release mechanism enabled a controlled and sustained release of the drug, ensuring prolonged therapeutic effects while minimizing off-target effects. These findings highlight the potential of smart nanomedicine systems to improve the therapeutic outcomes of cancer treatments by optimizing drug delivery and reducing systemic toxicity.

Future research should focus on refining the design of smart nanomedicine systems to optimize their efficacy and safety (Yazdani et al., 2026). Key areas for improvement include enhancing the targeting capabilities of nanoparticles, improving the responsiveness of drug release to various environmental cues, and evaluating the long-term safety of these systems in clinical trials. Moreover, combining smart nanoparticles with other therapeutic modalities, such as gene therapy or immunotherapy, could provide a synergistic effect, further improving the treatment of cancer and other diseases. Clinical trials are essential to confirm the safety, biocompatibility, and therapeutic efficacy of smart nanomedicine systems in human patients. As research continues to advance, smart nanomedicine systems could become a cornerstone of precision medicine, providing more personalized, effective, and less toxic treatment options for cancer patients.

CONCLUSION

The most significant finding of this study is the enhanced precision in drug release and the substantial reduction in toxicity achieved through the use of smart nanomedicine systems. The nanoparticle-based systems demonstrated superior targeting efficiency, with 60% greater drug retention at the tumor site and a 40% reduction in systemic toxicity compared to conventional drug delivery methods. These systems were able to deliver chemotherapeutic agents precisely to the tumor site while minimizing the exposure of healthy tissues to harmful drugs, thus improving the therapeutic index and reducing adverse side effects. The ability to control the release of drugs in response to environmental stimuli, such as pH or temperature, makes these nanomedicine systems highly effective for precise drug delivery in cancer therapy.

This research makes a significant contribution by integrating smart, stimuli-responsive nanomaterials into cancer treatment, offering a more targeted and efficient method of drug delivery. While previous studies focused on traditional drug delivery systems or passive targeting mechanisms, this research emphasizes the active, responsive nature of nanoparticles that respond to specific cues within the tumor microenvironment. The study also provides valuable insights into optimizing nanoparticle properties, such as size, surface charge, and functionalization, to enhance their efficacy and minimize off-target effects. These contributions advance the understanding of how nanomedicine can be utilized to create more personalized and effective therapies, with the potential to revolutionize cancer treatment.

Despite the promising results, several limitations in this study require further investigation. The long-term biocompatibility and safety of the smart nanomedicine systems, particularly their potential accumulation in non-target organs, have not been fully explored. While the study demonstrated reduced toxicity in non-target tissues, further research is needed to assess the chronic effects of these nanoparticles over extended periods. Additionally, the clinical translation of these systems needs to be addressed, particularly in terms of scalability, manufacturing feasibility, and regulatory approval. Future studies should also focus on combining smart nanomedicine systems with other therapeutic modalities, such as gene therapy or immunotherapy, to enhance their efficacy and broaden their applications in precision medicine.

Future research should explore the optimization of smart nanomedicine systems to improve their performance in various clinical settings. The next steps involve refining nanoparticle formulations to enhance their targeting efficiency and responsiveness to environmental stimuli, as well as evaluating their performance in larger, more diverse animal models. Clinical trials will be necessary to validate the findings of this study and establish the

long-term safety and efficacy of nanoparticle-based systems in human patients. Furthermore, investigating the integration of smart nanomedicine systems with other diagnostic and therapeutic technologies, such as imaging or gene therapy, could provide even more precise treatment options. Ultimately, the successful development of these systems could lead to a significant advancement in cancer therapy, providing patients with more effective and less toxic treatment options tailored to their specific needs.

DECLARATION OF AI AND AI ASSISTED TECHNOLOGIES IN THE WRITING PROCESS

During the preparation of this manuscript, the author(s) used Grammarly to assist in improving grammar, language quality, and overall readability of the text. After using this tool, the author(s) carefully reviewed and edited the content as necessary and take full responsibility for the content of the publication.

AUTHOR CONTRIBUTIONS

Author 1: Conceptualization; Project administration; Validation; Writing - review and editing.

Author 2: Conceptualization; Data curation; In-vestigation.

Author 3: Data curation; Investigation.

DECLARATION OF COMPETING INTEREST

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

REFERENCES

Abdoh, A., Imran, M., Al-Smadi, K., Kaur, H., Ali, M., Kumeria, T., & Mohammed, Y. (2026). Stimuli-responsive smart nanocarriers for skin drug delivery. *International Journal of Pharmaceutics*, *691*, 126534. https://doi.org/10.1016/j.ijpharm.2025.126534

Ahmad, Q., Mehdi, S., Shaukat, B., Siddique, R., Asif, M. T., Malik, A., Khan, S., Siddiqui, R., Khan, N. A., & Mehmood, M. H. (2026). Multi-stimuli responsive nanoparticles: Next-generation platforms for smart drug delivery. *OpenNano*, *29*, 100296. https://doi.org/10.1016/j.onano.2026.100296

Alam, M. A. (2026). Emerging smart nanocarrier based drug delivery systems for cancer therapeutics. *Next Nanotechnology*, *9*, 100387. https://doi.org/10.1016/j.nxnano.2026.100387

Bajgiran, N. K., Ahmadi, Y., & Majidi, S. (2025). Smart nanoparticles for responsive drug delivery in Diabetes: Advances, Challenges, and future Perspectives. *International Journal of Pharmaceutics*, *681*, 125817. https://doi.org/10.1016/j.ijpharm.2025.125817

Cagil, E. M., Yakhshilikova, L., & Ersoz, M. (2026). Smart bioconjugated MOFs for targeted drug delivery: Albumin and globulin effects on mebeverine release dynamics. *Nanomedicine: Nanotechnology, Biology and Medicine*, *71*, 102882. https://doi.org/10.1016/j.nano.2025.102882

Chen, Y., Guo, Z., Li, J., Wang, K., & Huang, J. (2025). Smart nucleic acid nanodrug delivery system for precision therapeutics. *Coordination Chemistry Reviews*, *535*, 216673. https://doi.org/10.1016/j.ccr.2025.216673

Chowdhury, S., Sarkar, S., Das, A., Kar, K., & Chakraborty, P. (2026). Next-generation smart drug delivery: Biosensor-integrated closed-loop therapeutics (CLT) for regenerative medicine. *Next Bioengineering*, *2*, 100027. https://doi.org/10.1016/j.nxbio.2026.100027

Datta, D., Colaco, V., Nison, M., H, A. P., Bandi, S. P., Dhas, N., Pai, V. R., Halagali, P., Tippavajhala, V. K., Singh, S., & Vora, L. K. (2026). Smart microdevices for biomedical drug delivery: Endogenous stimuli as the key to safer therapeutics. *RSC Advances*, *16*(16), 14878–14935. https://doi.org/10.1039/d5ra09767c

Davarpanah, F., Safari, J., & Masaeli, E. (2026). Injectable smart hydrogel with dual pH/thermal responsiveness: A PCL–PEG–PCL/niosome synergistic platform for precision drug delivery. *Biomaterials Advances*, *179*, 214527. https://doi.org/10.1016/j.bioadv.2025.214527

Deepti, A., Jose, J., Saidumohamed, B. E., & Govind, S. (2026). Chapter 14—Smart systems for the management of cerebrovascular accidents: Integrating artificial intelligence with targeted drug delivery. In C. P. Sharma, F. G. Thankam, & R. Goswami (Eds.), *AI Powered Drug delivery to Neuro and Cardiovascular Systems* (pp. 371–405). Academic Press. https://doi.org/10.1016/B978-0-443-40441-2.00003-2

Emadi, R., Amiri, Z., Mortazavi Moghadam, F., Raoufi, S., Zargar Moradi, M., Asadi, S., C. Cho, W., Park, J. H., Voosough, A., Ramezani Farani, M., Hwang, S.-K., & Huh, Y. S. (2026). Self-assembling nanocomposites for smart drug delivery: Towards personalized and stimuli-responsive therapeutics. *RSC Advances*, *16*(6), 5088–5127. https://doi.org/10.1039/d5ra07117h

Esmaeilpour, D., Ghavami, S., Zarrabi, A., Khosravi, A., Zarepour, A., Cordani, M., Klionsky, D. J., Hamblin, M. R., & Sillanpää, M. (2026). Artificial-intelligence-guided autophagy modulation and nanomedicine design for precision photodynamic cancer therapy. *Drug Discovery Today*, *31*(3), 104633. https://doi.org/10.1016/j.drudis.2026.104633

Filiz, A., Ölçeroğlu, B., Çiçek, şevval, Aydın Turna, S., Çetintürk, K., & Barlas, F. B. (2026). Engineering smart nanoplatforms for doxorubicin: Recent advances in stimuli-responsive drug delivery systems. *Journal of Drug Delivery Science and Technology*, *122*, 108452. https://doi.org/10.1016/j.jddst.2026.108452

Fu, Z., Zhou, D., Liu, Z., & Ni, D. (2025). GSH-responsive nanomedicine for disease smart imaging and therapy. *Coordination Chemistry Reviews*, *533*, 216554. https://doi.org/10.1016/j.ccr.2025.216554

Guo, F., & Pan, Y. (2025). Targeting lung cancer utilizing smart nanoparticles: Nanomedicine meets tumor stroma. *Bioorganic Chemistry*, *167*, 109202. https://doi.org/10.1016/j.bioorg.2025.109202

Hassan, A., Zameer, M. D., Khan, M., Hassan, T., Umair, M., Iqbal, M. N., Ahi, M. J., Gul, P., & Ahmed, N. (2026). Smart nanocarriers for biosimilars: A new frontier in targeted drug delivery. *Journal of Drug Delivery Science and Technology*, *116*, 107955. https://doi.org/10.1016/j.jddst.2025.107955

Hu, S., Zhao, R., Yang, S., Li, Y., Yin, W., Yu, S., Lyu, B., & Shen, Y. (2026). Smart nanodelivery systems for overcoming nitric oxide instability and enabling disease specific therapies. *Applied Materials Today*, *48*, 103058. https://doi.org/10.1016/j.apmt.2025.103058

Hu, Y., Yang, X., Shu, F., Jin, L., Sarsaiya, S., Han, S., & Chen, J. (2026). Smart exosomes: Multimodal engineering strategies for logic-gated and stimuli-responsive precision theranostics. *International Journal of Pharmaceutics*, *698*, 126846. https://doi.org/10.1016/j.ijpharm.2026.126846

Huang, X., Ji, M., Shang, X., Zhang, H., Zhang, X., Zhou, J., & Yin, T. (2025). Smart on-demand drug release strategies for cancer combination therapy. *Journal of Controlled Release*, *383*, 113782. https://doi.org/10.1016/j.jconrel.2025.113782

Jain, M., Sheikh, A., Alqahtani, T., Shmrany, H. A., Gupta, G., Goh, K. W., & Kesharwani, P. (2026). Dextran-engineered smart nanosystems for intelligent tumor drug targeting. *Critical Reviews in Oncology/Hematology*, *220*, 105173. https://doi.org/10.1016/j.critrevonc.2026.105173

Kar, N. P., Lin, J., HassankhaniRad, A., Li, W., Aboushanab, A. R., Li, Y., & Sun, J. (2025). Smart polymeric nanoparticles for targeted delivery and microenvironment-responsive therapy in pancreatic cancer. *Smart Materials in Medicine*, *6*(3), 368–386. https://doi.org/10.1016/j.smaim.2025.09.003

Khan, S., Saeed, M., Gupta, G., Alsayari, A., Wahab, S., Goh, K. W., & Kesharwani, P. (2025). Smart nanoparticle delivery systems for resveratrol: A targeted strategy to enhance anticancer efficacy and bioavailability. *Microchemical Journal*, *218*, 115307. https://doi.org/10.1016/j.microc.2025.115307

Khatri, D., Wani, B. G., Mir, M., Chauhan, A., & Chauhan, D. (2026). Chapter 6—Advanced drug delivery strategies: Nanoparticles, liposomes, dendrimers, and smart biomaterials. In S. Banerjee & D. Bhatia (Eds.), *Novel and Innovative Drug Delivery Systems to Overcome Chemoresistance in Human Malignancies* (pp. 145–167). Academic Press. https://doi.org/10.1016/B978-0-443-45717-3.00001-5

Li, X., Yu, W., Zhang, Y., Zhao, H., Wang, J., Sun, M., Xing, D., & Wang, C. (2026). Tumor microenvironment-responsive self-assembled drug-drug conjugate nanosystems: A smart platform for precision cancer therapy. *Coordination Chemistry Reviews*, *547*, 217097. https://doi.org/10.1016/j.ccr.2025.217097

Liang, C., Zhang, T., Zhang, Q., & Mou, X. (2025). Smart self-assembled nanomedicine for ferroptotic tumor therapy. *Colloid and Interface Science Communications*, *66*, 100829. https://doi.org/10.1016/j.colcom.2025.100829

Mousavi, S. M., Abbasifard, M., Abbasi, R., Tivay, S., Hosseini, H., Taghipoor, M., Kalashgrani, M. Y., Aljabri, M. D., Rahman, M. M., Chiang, W.-H., & Ghahramani, Y. (2025). Smart nano exosomes as precision drug carriers: A new frontier in targeted treatment of oral cancer. *International Journal of Pharmaceutics*, *682*, 125923. https://doi.org/10.1016/j.ijpharm.2025.125923

Singh, M., Singh, S., Sharma, P., Bhandari, R., Sharma, N., Rajput, R., Gupta, V., Singh, S. K., Dua, K., Chitranshi, N., & Basu, S. (2026). Smart Lipid-Based Nanocarrier System for the Topical Delivery of Ocular Therapeutics Bio-Interfacing, Physicochemical Diversity, and Routing Barriers. *European Journal of Pharmaceutical Sciences*, 107506. https://doi.org/10.1016/j.ejps.2026.107506

Soleymani, S., Naghib, S. M., & Mozafari, M. R. (2025). pH/ Temperature/ Redox and Light-responsive Polymersome Structure and Application in Cancer Therapy: Smart Drug Delivery and Targeted Drug Release. *Current Medicinal Chemistry*, *32*(22), 4456–4480. https://doi.org/10.2174/0109298673303351240507113603

Tan, J., Geng, W., Ju, T., Liu, S., Chen, Z., Li, P., Liu, K., Liu, X., Zhao, Q., Wang, K., & Liu, H. (2026). From natural product to nanomedicine: Advances in smart capsaicin delivery systems for the treatment of complex diseases. *Sustainable Materials and Technologies*, e02095. https://doi.org/10.1016/j.susmat.2026.e02095

Verma, A. K., Singh, A., Singh, A. K., Maurya, P. S., Jaiswal, V., & Sachan, V. (2026). Precision veterinary therapeutics through nanomedicine: Platforms, applications, and One Health implications. *Next Research*, *9*, 101747. https://doi.org/10.1016/j.nexres.2026.101747

Wang, Z.-X., Wang, S.-Y., Wang, Z., Liu, Y., & Wu, F.-G. (2026). Smart photo-enabled micelles for cancer therapy: Mechanisms, challenges, and innovations. *Journal of Controlled Release*, *390*, 114474. https://doi.org/10.1016/j.jconrel.2025.114474

Yazdani, S., Mozaffarian, M., Pazuki, G., & Hadidi, N. (2026). Artificial intelligence-assisted design and optimization of stimuli-responsive nanocarriers for smart drug delivery. *Materials Today Bio*, *38*, 103153. https://doi.org/10.1016/j.mtbio.2026.103153

Younas, A., Wang, S., Asad, M., Al Mamun, A., Majeed, S., Sharif, A., Zhou, Q., Liu, Y., Geng, P., Shao, C., & Xiao, J. (2026). Recent advances in cancer nanomedicine: From

smart targeting to personalized therapeutics—Pioneering a new era in precision oncology. *Materials Today Bio*, *36*, 102660. https://doi.org/10.1016/j.mtbio.2025.102660

Zhang, P., Pan, J., Lin, S., Peng, B., An, C., Zhang, J., Xu, L., Lai, Y., Yu, H., & Xu, Z. (2025). Smart drug delivery platforms reprogramming cancer immune cycle to mitigate immune resistance of pancreatic tumors. *Advanced Drug Delivery Reviews*, *224*, 115620. https://doi.org/10.1016/j.addr.2025.115620

Zhao, Y., Zhang, Z., Yang, X., & Li, Z. (2025). Progress on hydroxyethyl starch-based smart nanomedicines. *Precision Medicine and Engineering*, *2*(3), 100041. https://doi.org/10.1016/j.preme.2025.100041

Zhu, R., Yu, X., Zhang, Y., Zhang, J., Li, S., Li, D., & Ma, Y. (2026). Smart stimuli-responsive polymeric nanoparticles in precision cancer therapy: From tumor microenvironment triggers to controlled release. *Chemical Engineering Journal*, *534*, 175025. https://doi.org/10.1016/j.cej.2026.175025